← Back to guidelines
Plastic Surgery3 papers

Tinea faciei

Last edited:

Overview

Tinea faciei, more accurately referred to as lupus miliaris disseminatus faciei (LMDF), is a chronic inflammatory dermatosis characterized by multiple, uniform, reddish, translucent skin lesions predominantly affecting the facial regions. Historically, this condition was speculated to be associated with tuberculosis, rosacea, and sarcoidosis, but current understanding recognizes it as a distinct clinical entity [PMID:25148286]. The pathophysiology involves a dermal granulomatous reaction with central areas of necrosis and occasional degeneration of hair follicles, distinguishing it from other granulomatous conditions [PMID:23552001]. Clinically, LMDF presents with micropapular eruptions that can lead to scarring, necessitating careful diagnosis and management to prevent long-term disfigurement.

Pathophysiology

Lupus miliaris disseminatus faciei (LMDF) is now firmly established as a distinct clinical entity, separate from historically speculated associations with tuberculosis, rosacea, and sarcoidosis [PMID:25148286]. Histological examination of affected skin reveals characteristic features, including a dermal granulomatous reaction with central zones of necrosis. This granulomatous process often involves degenerated hair follicles, contributing to the unique histopathological profile of LMDF [PMID:23552001]. The exact etiology remains unclear, but these pathological findings suggest an immune-mediated mechanism, possibly involving chronic inflammation and follicular involvement, which differentiates LMDF from other granulomatous dermatoses.

Clinical Presentation

The clinical presentation of LMDF is highly characteristic, typically manifesting as multiple, uniform, reddish, translucent papules predominantly distributed across the face. These lesions often appear micropapular and can coalesce, leading to a distinctive appearance that is crucial for clinical recognition [PMID:27356779]. A case report detailed a young male patient presenting with asymptomatic micropapular eruptions localized to the midface, aligning well with the typical presentation of LMDF [PMID:23552001]. Additionally, scarring has been noted in some patients, indicating the potential for significant cosmetic impact if left untreated. These clinical features are pivotal in distinguishing LMDF from other facial dermatoses and underscore the importance of early diagnosis.

Diagnosis

Diagnosing LMDF involves a thorough clinical evaluation that integrates characteristic clinical features with histopathological confirmation. The clinical criteria include the presence of multiple, uniform, reddish, translucent papules predominantly on the face, often with a history of scarring [PMID:27356779]. Histological examination is essential, revealing the hallmark dermal granulomatous reaction with central necrosis and follicular involvement [PMID:23552001]. It is crucial to rule out other granulomatous conditions such as tuberculosis, rosacea, and sarcoidosis, as these were historically linked but are now recognized as distinct entities [PMID:25148286]. In clinical practice, a biopsy with histopathological analysis remains the gold standard for confirming the diagnosis and differentiating LMDF from similar dermatoses.

Differential Diagnosis

Differentiating LMDF from other granulomatous conditions such as tuberculosis, rosacea, and sarcoidosis is critical due to the historical overlap and overlapping clinical features [PMID:25148286]. Tuberculosis can present with granulomatous lesions but typically involves systemic symptoms and broader organ involvement. Rosacea often presents with erythematous papules and pustules, predominantly affecting the central face but lacks the characteristic micropapular and translucent nature seen in LMDF. Sarcoidosis, while also granulomatous, usually exhibits systemic manifestations and can involve multiple organs, distinguishing it from the localized facial presentation of LMDF. Accurate differentiation relies on clinical presentation, histopathological findings, and exclusion of systemic involvement, ensuring appropriate management strategies are applied.

Management

The management of LMDF often adopts a conservative approach, recognizing the self-limiting nature of the lesions in many cases [PMID:25148286]. However, treatment is tailored to alleviate symptoms and prevent scarring, which can be a significant concern. A case study highlighted notable improvement in disfiguring scars following photodynamic therapy in a 54-year-old male patient, suggesting this modality as a potential therapeutic option for managing scarring associated with LMDF [PMID:27356779]. Systemic treatments have also shown moderate efficacy; for instance, a case report documented improvement with doxycycline, indicating that antibiotics might play a role in controlling inflammation [PMID:23552001]. Topical therapies, including corticosteroids and calcineurin inhibitors, are frequently employed to manage active lesions and reduce inflammation. The choice of treatment should be individualized based on the severity of symptoms, extent of scarring, and patient preference, with close monitoring for response and potential side effects.

Complications

One of the most significant complications of LMDF is the development of disfiguring scars, which can profoundly impact a patient's quality of life and psychological well-being [PMID:27356779]. Conventional therapeutic approaches, while effective in managing active lesions, often fall short in preventing or adequately treating scarring. This underscores the necessity for early intervention and the exploration of advanced therapeutic modalities such as photodynamic therapy to mitigate long-term cosmetic consequences. Additionally, chronic inflammation and persistent lesions can lead to persistent discomfort and functional impairment, further emphasizing the importance of comprehensive management strategies that address both the active disease and its sequelae.

Key Recommendations

  • Clinical Recognition: Early recognition of LMDF based on characteristic micropapular, reddish, translucent facial lesions is crucial for timely intervention.
  • Histopathological Confirmation: Biopsy and histopathological examination are essential for confirming the diagnosis and differentiating from other granulomatous conditions.
  • Conservative Management: Initiate conservative management strategies, including topical corticosteroids and calcineurin inhibitors, to control inflammation and prevent scarring.
  • Advanced Therapies: Consider advanced treatments like photodynamic therapy for patients with significant scarring to improve cosmetic outcomes.
  • Systemic Options: Evaluate systemic treatments such as doxycycline for moderate to severe cases, monitoring for efficacy and side effects.
  • Patient Monitoring: Regular follow-up is necessary to assess response to treatment and manage potential complications, particularly scarring and psychological impact.
  • References

    1 Borgia F, Giuffrida R, Vaccaro M, Lentini M, Cannavò SP. Photodynamic therapy in lupus miliaris disseminatus faciei's scars. Dermatologic therapy 2016. link 2 Mandal RK, De Sarkar A, Ghosh SK. Self regressing skin-colored papules with acneiform scarring over the face. Dermatology online journal 2014. link 3 Rocas D, Kanitakis J. Lupus miliaris disseminatus faciei: report of a new case and brief literature review. Dermatology online journal 2013. link

    Original source

    1. [1]
      Photodynamic therapy in lupus miliaris disseminatus faciei's scars.Borgia F, Giuffrida R, Vaccaro M, Lentini M, Cannavò SP Dermatologic therapy (2016)
    2. [2]
      Self regressing skin-colored papules with acneiform scarring over the face.Mandal RK, De Sarkar A, Ghosh SK Dermatology online journal (2014)
    3. [3]
      Lupus miliaris disseminatus faciei: report of a new case and brief literature review.Rocas D, Kanitakis J Dermatology online journal (2013)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG